Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

To access The New England Journal of Medicine publication on the interim results from the ANNEXA-4 study of andexanet, visit: and NEJM ANNEXA-4 Supplement

Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Investor Event During J.P. Morgan Healthcare Conference
Tuesday, January 10, 2017 7:00 a.m. PT
Supporting Materials
Download Event Supporting Material Portola Presentation

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.61 (2.40%)
Data as of 01/20/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
01/03/17Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor webcast to review recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 10, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. During the investor event, Portola’s senior managemen... 
Printer Friendly Version
12/23/16Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) accepted Portola's New Drug Application (NDA) granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six mo... 
Printer Friendly Version
12/19/16Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced it has signed a $50 million loan agreement with Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) that provides additional funding toward development and clinical studies of AndexXa™ (andexanet alfa), an investigational compound that is a potential antidote for Factor Xa inhibitors.  “This agreement reflects the commitment and support of the andexanet a... 
Printer Friendly Version
11/28/16Portola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
South San Francisco, Calif. (November 28, 2016) – Portola Pharmaceuticals (Nasdaq: PTLA) today announced that clinical and preclinical results from studies of all three of its investigational drugs -- AndexXa™ (andexanet alfa), betrixaban and cerdulatinib -- will be presented at the upcoming 58th American Society of Hematology (ASH) Annual Meeting and Exposition, which is taking place from December 3-6 at the San Diego Convention Center.AndexXa, a U.S. Food and Drug Administration (FDA)-d... 
Printer Friendly Version
11/14/16Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced results from three substudies of the pivotal Phase 3 APEX Study of betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant in development for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Findings from the analyses were presented by the PERFUSE Study Group at the American Heart Association (AHA) Scientific Sessio... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.